Merck strikes Daiichi deal that could be worth $22B

The latest stories trending on MedCity News.

Editor's Pick

Top Story Merck Missed on Seagen, But Comes Back With Potential $22B Daiichi ADC Deal After paying $4 billion up front, Merck will share in the development and commercialization of three Daiichi Sankyo cancer drugs in the red-hot field of antibody drug conjugates, or ADCs. The most advanced of them is on track for an FDA submission in 2024. Sponsored Content Hospitals Need to Cultivate a Culture of Informed Awareness Presented by Care Logistics and MedCity News In an upcoming webinar, learn how informed awareness can help hospitals overcome their most challenging operational challenges to simultaneously improve efficiency, staff engagement and satisfaction, quality of care, and profitability. Sign up today and join the conversation! Last Chance to Register Join us for INVEST Digital Health on Thursday, October 26th. Don't miss your chance to engage with our captivating lineup of speakers, network with more than 20 investors, and gain insights from pioneering startups in the FemTech sector, among other exciting opportunities. Secure Your Spot

Featured News

Why Holistic Care is Crucial After Receiving a Cancer Diagnosis Access to oncology-specific interdisciplinary care delivered digitally by a team of nurses, mental health therapists, nutritionists, advanced practice providers, and oncologists is the best option for combatting pain points related to both cost and access. America's Silent Liver Crisis: Are We Ready To Confront the Alarming Surge? We must prioritize early screening and diagnosis to facilitate timely interventions, prevent the progression to advanced liver disease and, ultimately, help save the lives of 1 in 10 Americans. FOLX Health Goes In-Network With Blue Shield of California, Other Insurers FOLX Health is now in-network with insurers, including Blue Shield of California. The company serves the LGBTQIA+ community and offers virtual primary care, one-on-one therapy, mental health medication management, hormone replacement therapy, pre-exposure prophylaxis and care navigation. Cedars-Sinai Develops Algorithm to Detect AFib in People Without Symptoms Cedars-Sinai published research in JAMA Cardiology this week on a algorithm it developed to detect atrial fibrillation in people not yet showing symptoms. The study found that the AI model does a good job of identifying hidden signals in common medical diagnostic testing and could help physicians better prevent strokes and other heart-related complications in people with atrial fibrillation.

Resources

Heard at HLTH: Healthcare Execs Share Perspectives on AI, Virtual Health and Value-based Care As part of the Heard at HLTH video series, MedCity News Editor in Chief Arundhati Parmar and Senior Reporter Katie Adams interviewed healthcare executives about innovations in health tech at HLTH 2023 in Las Vegas earlier this month. Watch Now

MedCity News • PO Box 901 • New York, NY unsubscribe